Mirae Asset Global Investments Co. Ltd. Makes New $12.51 Million Investment in IQVIA Holdings Inc. $IQV

Mirae Asset Global Investments Co. Ltd. purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 46,530 shares of the medical research company’s stock, valued at approximately $12,510,000.

Other large investors have also made changes to their positions in the company. Korea Investment CORP acquired a new stake in IQVIA during the 2nd quarter worth approximately $13,918,000. Congress Asset Management Co. acquired a new position in shares of IQVIA in the third quarter valued at approximately $24,560,000. Deutsche Bank AG bought a new stake in shares of IQVIA during the second quarter worth $143,074,000. BlackRock Inc. bought a new stake in shares of IQVIA during the second quarter worth $2,811,292,000. Finally, National Pension Service raised its holdings in shares of IQVIA by 6.6% during the second quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock worth $72,646,000 after acquiring an additional 23,411 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $262.32 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. The business has a 50-day moving average of $266.22 and a 200-day moving average of $210.59. The stock has a market capitalization of $43.23 billion, a price-to-earnings ratio of 31.87, a PEG ratio of 2.30 and a beta of 1.16. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $284.50.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.26 by $0.08. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The business had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same quarter in the prior year, the company posted $3.00 earnings per share. IQVIA’s revenue was up 8.0% on a year-over-year basis. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Barclays boosted their price objective on shares of IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Robert W. Baird increased their target price on IQVIA from $324.00 to $328.00 and gave the stock an “outperform” rating in a report on Tuesday, October 27th. Mizuho lifted their price target on IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Stifel Nicolaus boosted their price target on IQVIA from $276.00 to $303.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Finally, HSBC upped their price objective on IQVIA from $280.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, September 1st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $294.21.

Insider Transactions at IQVIA

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.